/Company Directory

/

Asset Brief

Generic dermatology portfolio

MYX·Mayne Pharma Group·Acne and other dermatological skin conditions·Approved·[ TODO: fill in ]

Plain-language Brief

The trial in plain terms

The disease: Acne vulgaris is a common inflammatory skin condition affecting the hair follicles and sebaceous glands, characterised by comedones, papules, pustules, and in more severe cases, nodules or cysts. It affects people of all ages but is most prevalent in adolescents and young adults. Other skin conditions in Mayne Pharma's dermatology portfolio include specific conditions and products covered.
What the asset is trying to do: Mayne Pharma's dermatology portfolio consists of approved generic and branded pharmaceutical products, primarily small molecules, targeting acne and other skin conditions. The specific active ingredients, formulations, and mechanisms of action across the full portfolio are as the company has not provided a consolidated product-level disclosure in the input data. Generic products by definition replicate the mechanisms of their reference-listed branded counterparts.
What the trial is measuring, and why it matters: As these assets are approved commercial products rather than investigational drugs in an active pivotal trial, the relevant performance metrics are commercial ones such as market share, net revenue, and prescription volume rather than clinical trial endpoints. Specific commercial performance data for the dermatology portfolio are and would be sourced from Mayne Pharma's periodic financial disclosures. No lead interventional trial is identified in the data provided for the acne or broader dermatology indication.
Efficacy benchmarks in this setting: Approved topical retinoids such as tretinoin and adapalene, as well as combination products (for example, adapalene plus benzoyl peroxide), have established efficacy benchmarks in acne, with specific response rates and inflammatory lesion count reductions documented in their respective US prescribing information and registration studies. Oral tetracycline-class antibiotics and hormonal therapies also have defined efficacy profiles in their labelling. Because the Mayne Pharma dermatology portfolio comprises approved generic and branded products rather than a novel investigational asset in an active comparative trial, early-stage versus approved-therapy comparisons are not applicable here.
Commercial context: Mayne Pharma's dermatology portfolio consists of products that have already received regulatory approval; the specific approved products, their approval dates, and approved indications are from a consolidated company disclosure. The company announced a new DistributeRx partnership with Resilia Pharmaceuticals on 26 May 2026 (per ASX announcement 2026-05-31), though the specific products and financial terms of that arrangement are . Whether the dermatology portfolio represents Mayne Pharma's lead revenue-generating segment relative to other company divisions is from the input data provided.

Sources for this brief (5)

Mayne Pharma ASX Announcements — DistributeRx Partnership with Resilia Pharmaceuticals · ASX / Mayne Pharma Group (MYX) · accessed 27 June 2026
Mayne Pharma 3Q Investor Presentation · Mayne Pharma Group (MYX) · accessed 27 June 2026
Mayne Pharma Jefferies Global Healthcare Conference Presentation · Mayne Pharma Group (MYX) · accessed 27 June 2026
FDA Approved Drug Products — Dermatology (Drugs@FDA) · US Food and Drug Administration · accessed 27 June 2026
Mayne Pharma Group Annual Report · Mayne Pharma Group (MYX) · accessed 27 June 2026

Trial Design

Design summary

Phase: Approved
Design type: [ TODO: fill in ] — no active interventional trial identified for the acne or dermatology indication in the data provided.
Primary endpoint: [ TODO: fill in ]
Key secondary endpoints: [ TODO: fill in ]
Enrolment target: [ TODO: fill in ]
Current enrolment status: [ TODO: fill in ] — no active recruiting trial identified in the input data for this indication.
Sites: [ TODO: fill in ]
Expected readout window: [ TODO: fill in ] — no active trial with a primary completion date is identified for this indication in the data provided.

Asset Track Record

Did MYX deliver against its own guidance?

Past catalysts on this ticker, reconciled against the announcement parse pipeline. Hover any row for the parsed outcome detail.

30 June 2026commercial milestoneRHOFADE generic competition entryoverdue
30 June 2026regulatory decisionCosette appeal decisionoverduesrc ASX ↗
5 June 2026otherMayne Pharma receives $14.4m for legal costs from Cosettehitsrc ASX ↗
31 May 2026partnershipNew DistributeRx partnership with Resilia Pharmaceuticalshitsrc ASX ↗
22 May 2026otherCourt awards MYX $13.27m for legal costs from Cosettehitsrc ASX ↗

Class Catalyst Calendar

What's landed, what's next for Generic dermatology portfolio and peers

Generic dermatology portfolio's own upcoming catalysts alongside class-defining historical readouts and upcoming primary completion dates in the same mechanism classes. Each event moves the broader thesis for Generic dermatology portfolio. Showing past 6 months and next 12 months · 3 later hidden.

ConferenceAACR Annual Meeting 2026· ChicagoApr 2026
ConferenceASCO Annual Meeting 2026· ChicagoMay 2026
Today
A Study to Test the Long-term Treatment of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa

Trial design comparison

How Generic dermatology portfolio reads against active peer trials

Same axes, same units. Discontinued and historical pivotal trials excluded; see Competitor Landscape below for the full set.

Trial	Sponsor	Class	Phase / Line	Design	Primary endpoint	Dosing	Key eligibility	n
Generic dermatology portfolio	Mayne Pharma Group	Small Molecule Other	Approved[ TODO: fill in ]	[ TODO: fill in ] — no active interventional trial identified for the acne or dermatology indication in the data provided.	[ TODO: fill in ]	[ TODO: fill in ]	[ TODO: fill in ]	0
Anti-inflammatory Effects of Topical Erythromycin and Clindamycin in Acne Patients

Competitor Landscape

Competing programmes by mechanism and phase

Read-across commentary attached per trial. Phase ordering preserved within each group.

Mechanism trade-offs· 1 classes comparedexpand ›

Mechanism	Speed to patient	Manufacturing	Best approved result	Durability	Moat
Antisense oligonucleotideASO	Off-the-shelf	Synthetic	Approved (SMA/DMD)	Chronic dosing	Moderate

OtherASX peers ›

Curated Commentary

Third-party coverage(none curated yet)

expand ›

External analyst notes, journalism, and industry commentary cited with attribution.

No third-party coverage curated for Generic dermatology portfolio yet. Broker coverage of Mayne Pharma Group is thin; named analyst notes will appear here as they become available. For now, see the company's ASX announcements and the linked sponsor / class sources elsewhere on this page.

Asset Track Record

Did MYX deliver against its own guidance?

Past catalysts on this ticker, reconciled against the announcement parse pipeline. Hover any row for the parsed outcome detail.

30 June 2026commercial milestoneRHOFADE generic competition entryoverdue
30 June 2026regulatory decisionCosette appeal decisionoverduesrc ASX ↗
5 June 2026otherMayne Pharma receives $14.4m for legal costs from Cosettehitsrc ASX ↗
31 May 2026partnershipNew DistributeRx partnership with Resilia Pharmaceuticalshitsrc ASX ↗
22 May 2026otherCourt awards MYX $13.27m for legal costs from Cosettehitsrc ASX ↗

Class Catalyst Calendar

What's landed, what's next for Generic dermatology portfolio and peers

ConferenceAACR Annual Meeting 2026· ChicagoApr 2026
ConferenceASCO Annual Meeting 2026· ChicagoMay 2026
Today
A Study to Test the Long-term Treatment of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa

Trial design comparison

How Generic dermatology portfolio reads against active peer trials

Same axes, same units. Discontinued and historical pivotal trials excluded; see Competitor Landscape below for the full set.

Trial	Sponsor	Class	Phase / Line	Design	Primary endpoint	Dosing	Key eligibility	n
Generic dermatology portfolio	Mayne Pharma Group	Small Molecule Other	Approved[ TODO: fill in ]	[ TODO: fill in ] — no active interventional trial identified for the acne or dermatology indication in the data provided.	[ TODO: fill in ]	[ TODO: fill in ]	[ TODO: fill in ]	0
Anti-inflammatory Effects of Topical Erythromycin and Clindamycin in Acne Patients

Competitor Landscape

Competing programmes by mechanism and phase

Read-across commentary attached per trial. Phase ordering preserved within each group.

Mechanism trade-offs· 1 classes comparedexpand ›

Mechanism	Speed to patient	Manufacturing	Best approved result	Durability	Moat
Antisense oligonucleotideASO	Off-the-shelf	Synthetic	Approved (SMA/DMD)	Chronic dosing	Moderate

OtherASX peers ›

Generic dermatology portfolion = 0

Mayne Pharma Group·Small Molecule Other·Approved·[ TODO: fill in ]

Design: [ TODO: fill in ] — no active interventional trial identified for the acne or dermatology indication in the data provided.
Primary endpoint: [ TODO: fill in ]
Dosing: [ TODO: fill in ]
Eligibility: [ TODO: fill in ]

Anti-inflammatory Effects of Topical Erythromycin and Clindamycin in Acne Patientsn = —

Centre for Human Drug Research, Netherlands·—·Phase 4

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

Efficacy and Safety of Adapalene Gel and Hyaluronic Acid Versus Adapalene Gel Alone in Mild to Moderate Acne Vulgarisn = —

Badr University·—·Phase 4

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

Comparative Effectiveness Study of Spironolactone Versus Doxycycline for Acnen = —

University of Pennsylvania·—·Phase 4

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

A Study to Assess Sebaceous Gland Changes and Constituents of Sebum (Skin Oil) Induced by Clascoterone 1% Cream in Acne Patientsn = —

Sun Pharmaceutical Industries Limited·—·Phase 4

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

Randomized, Triple-Blind, Placebo-Controlled Trial of Topical Dapsone Gel in Patients With Acne Vulgarisn = —

Oya Helin Dundar·—·Phase 4

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

Metronidazole 2% Gel Versus Clindamycin 1% Gel for Moderate Acne Vulgarisn = —

Jinnah Postgraduate Medical Centre·—·Phase 4

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

Comparison of the Clinical Efficacy and Safety of Topical and Subcutaneous Injection of Secukinumab in HSn = —

Peking Union Medical College·—·Phase 4

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

Comparing Sarecycline and Doxycycline Effects on the Skin and Gut Bacteria in Acne.n = —

Integrative Skin Science and Research·—·Phase 4

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

Study to Assess Safety, Pharmacokinetics, and Treatment Effect of Cabtreon = —

Bausch Health Americas, Inc.·—·Phase 4

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

Extension Study to Assess Effects of Non-interrupted Versus Interrupted and Long Term Treatment of Two Dose Regimes of Secukinumab in Subjects With Hidradenitis Suppurativan = —

Novartis Pharmaceuticals·—·Phase 3

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

Serum Intercellular Adhesion Molecule -1 in Acne Vulgaris Patients : Effect of Montelukastn = —

South Valley University·—·Phase 3

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

The Effectiveness and Safety of Cleanser Containing Triethyl Citrate, Pyruvic Acid, Combination Cream Containing Triethyl Citrate, Ethyl Linoleate, GT Peptide-10, Salicylic Acid 0,5%, Zinc Lactate, Hyaluronic Acid and Spot Cream Containing Triethyl Citrate, Ethyl Linoleate, GT Peptide-10, Honokioln = —

Dr.dr.Irma Bernadette, SpKK (K)·—·Phase 3

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

A Study to Assess Efficacy and Safety of N-Acetyl-GED-0507-34-LEVO Gel 5% in Patients With Acne Vulgaris (GEDACNE 2)n = —

PPM Services S.A.·—·Phase 3

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

A Study to Assess Efficacy and Safety of N-Acetyl-GED-0507-34-LEVO Gel 5%, in Patients With Acne Vulgaris (GEDACNE-1)n = —

PPM Services S.A.·—·Phase 3

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

A Long-term Safety and Efficacy Study of N-Acetyl-GED-0507-34-LEVO Gel 5%, in Subjects With Acne Vulgaris (GEDACNE-LT)n = —

PPM Services S.A.·—·Phase 3

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

A Study to Test the Long-term Treatment of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativan = —

UCB Biopharma SRL·—·Phase 3

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

Clinical Trial to Compare Oral Isotretinoin to Standard of Care in Moderate Acne Skin of Color Patientsn = —

Centre Hospitalier Universitaire de Nice·—·Phase 3

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

Efficacy and Safety of Clascoterone Cream 1% in Facial Acne Vulgarisn = —

Zhejiang Sunshine Mandi Pharmaceutical Co.,Ltd.·—·Phase 3

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativan = —

Incyte Corporation·—·Phase 3

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

A Study to Compare the Efficacy, Safety and Pharmacokinetics of Trifarotene 50 mcg/g Cream in Chinese Subjects With Acne Vulgarisn = —

Galderma R&D·—·Phase 3

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

Study of New Antiandrogenic Progestogen + Low-dose Estrogen for Moderate Acne Vulgarisn = —

Eurofarma Laboratorios S.A.·—·Phase 3

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa (RECHARGE 1)n = —

Novartis Pharmaceuticals·—·Phase 3

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativan = —

Novartis Pharmaceuticals·—·Phase 3

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

1% Clascoterone Cream for the Treatment Acne Vulgarisn = —

Zhejiang Sunshine Mandi Pharmaceutical Co.,Ltd.·—·Phase 3

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

A Full Face Study to Evaluate the Efficacy of Dermapen 4™ Microneedling Device in Addition with MG-CLR Serum for Acne Treatment Over 12 Weeks.n = —

Equipmed USA LLC·—·PHASE2/PHASE3

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

Effectiveness and Safety of Zingiber Officinale Transdermal Patch for Acne Vulgaris; Study of Interleukin 1 and Skin Microbiomen = —

Hasanuddin University·—·PHASE2/PHASE3

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

A Study Evaluating BFB759 in Moderate to Severe Hidradenitis Suppurativan = —

Bluefin Biomedicine, Inc.·—·PHASE2/PHASE3

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

Study of Efficacy and Safety of Investigational Treatments in Patients With Moderate to Severe Hidradenitis Suppurativan = —

Novartis Pharmaceuticals·—·Phase 2

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

Study to Evaluate the Safety and Efficacy of BF-200 ALA (Ameluz®) and BF-RhodoLED® in the Treatment of Moderate to Severe Acne Vulgaris With Photodynamic Therapy in Adultsn = —

Biofrontera Inc.·—·Phase 2

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

The Relationship Between Microbioma Balance and Acne Vulgaris as a New Acne Treatmentn = —

Universitas Padjadjaran·—·Phase 2

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

Anifrolumab for Hidradenitis Suppurativan = —

University of North Carolina, Chapel Hill·—·Phase 2

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

A Study to Evaluate the Efficacy and Safety of AVTX-009 in Patients With Moderate to Severe Hidradenitis Suppurativan = —

Avalo Therapeutics, Inc.·—·Phase 2

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

Topical Application of Engineered Lactobacillus Reuteri With a Zinc Sulfate-Tannic Acid MPN Coating for Acnen = —

Shenzhen People's Hospital·—·Phase 2

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

Study to Evaluate the Efficacy, Safety and Tolerability of Photodynamic Therapy(PDT) With Chlorin-e6 in Treating Moderate to Severe Acnen = —

Xiyuan Hospital of China Academy of Chinese Medical Sciences·—·Phase 2

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

Topical 5% Spironolactone Gel Versus 0.1% Adapalene Gel for Acne Vulgaris: A Randomized Split-Face Studyn = —

Assiut University·—·Phase 2

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

Safety, Efficacy and Pharmacokinetic Characteristics of KR230109 Cream in Facial Acne Vulgarisn = —

Jiangxi Kvvit Pharmaceutical Co., Ltd.·—·Phase 2

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

Tibulizumab Skin Healing and Inflammation Evaluation for Lasting Defensen = —

Zura Bio Inc·—·Phase 2

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

Pharmacokinetics, Safety, and Efficacy of Povorcitinib in Adolescent Participants With Moderate to Severe Hidradenitis Suppurativan = —

Incyte Corporation·—·Phase 2

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

Clascoterone for Steroid-related Acne Vulgaris in Transgender Male Patients Receiving Masculinizing Hormone Therapyn = —

Stanford University·—·PHASE1/PHASE2

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

A Study to Evaluate Efficacy and Safety of HB0043 in Aadult Patients With Moderate to Severe Acne Vulgaris.n = —

Shanghai Huaota Biopharmaceutical Co., Ltd.·—·PHASE1/PHASE2

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

Lipidome and Microbiome Profile of Acnen = —

University of California, Davis·—·PHASE1/PHASE2

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

Comparative Effectiveness of Clindamycin-Retinoid, Clindamycin-Retinoid-Dexamethasone, and 10% SM-hUCMSC Secretome Gel in the Improvement of Mild-to-Moderate Acne Vulgarisn = —

Yohanes Firmansyah, dr, MH, MM·—·PHASE1/PHASE2

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

Study to Evaluate Safety, Efficacy and Immunogenicity of Acne mRNA Vaccine in Adults With Moderate to Severe Acnen = —

Sanofi Pasteur, a Sanofi Company·—·PHASE1/PHASE2

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

Study to Evaluate Safety, Efficacy and Immunogenicity of Acne mRNA Vaccine in Participants With Mild Acnen = —

Sanofi Pasteur, a Sanofi Company·—·PHASE1/PHASE2

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

CF
Anti-inflammatory Effects of Topical Erythromycin and Clindamycin in Acne Patients
Phase 4
Centre for Human Drug Research, Netherlands·Recruiting·Primary completion 1 June 2019·NCT03883269
1 site
PI: Robert Rissmann, PharmD
BU
Efficacy and Safety of Adapalene Gel and Hyaluronic Acid Versus Adapalene Gel Alone in Mild to Moderate Acne Vulgaris
Phase 4
Badr University·Recruiting·Primary completion 21 Oct 2025·NCT07102186
1 site
UO
Comparative Effectiveness Study of Spironolactone Versus Doxycycline for Acne
Phase 4
University of Pennsylvania·Active, not recruiting·Primary completion 14 Feb 2026·NCT04582383
18 sites·1 top centre: Penn / Abramson
SP
A Study to Assess Sebaceous Gland Changes and Constituents of Sebum (Skin Oil) Induced by Clascoterone 1% Cream in Acne Patients
Phase 4
Sun Pharmaceutical Industries Limited·Active, not recruiting·Primary completion 1 Mar 2026·NCT06425900
1 site
10 enrolledstalled · 188d
OH
Randomized, Triple-Blind, Placebo-Controlled Trial of Topical Dapsone Gel in Patients With Acne Vulgaris
Phase 4
Oya Helin Dundar·ENROLLING_BY_INVITATION·Primary completion 1 June 2026·NCT07244887
1 site
100 enrolled·PIs: Vildan Manav, MD, Assoc. Prof, Ayse Esra Koku Aksu, MD, Prof
JP
Metronidazole 2% Gel Versus Clindamycin 1% Gel for Moderate Acne Vulgaris
Phase 4
Jinnah Postgraduate Medical Centre·Not yet recruiting·Primary completion 1 Aug 2026·NCT07392047
0 sites
PU
Comparison of the Clinical Efficacy and Safety of Topical and Subcutaneous Injection of Secukinumab in HS
Phase 4
Peking Union Medical College·Not yet recruiting·Primary completion 30 Nov 2026·NCT07261072
1 site
IS
Comparing Sarecycline and Doxycycline Effects on the Skin and Gut Bacteria in Acne.
Phase 4
Integrative Skin Science and Research·Recruiting·Primary completion 1 Apr 2027·NCT07544251
BH
Study to Assess Safety, Pharmacokinetics, and Treatment Effect of Cabtreo
Phase 4
Bausch Health Americas, Inc.·Not yet recruiting·Primary completion 1 Dec 2027·NCT07524946
N
Extension Study to Assess Effects of Non-interrupted Versus Interrupted and Long Term Treatment of Two Dose Regimes of Secukinumab in Subjects With Hidradenitis Suppurativa
Phase 3
Novartis Pharmaceuticals·Active, not recruiting·Primary completion 26 May 2023·NCT04179175
191 sites
703 enrolled
SV
Serum Intercellular Adhesion Molecule -1 in Acne Vulgaris Patients : Effect of Montelukast
Phase 3
South Valley University·Not yet recruiting·Primary completion 1 Nov 2024·NCT06340984
0 sites
PIs: Hassan Mohammed Ibrahim, Assistant Professor, Abdulrahman Abdul Hamid Alsaied, Professor
DB
The Effectiveness and Safety of Cleanser Containing Triethyl Citrate, Pyruvic Acid, Combination Cream Containing Triethyl Citrate, Ethyl Linoleate, GT Peptide-10, Salicylic Acid 0,5%, Zinc Lactate, Hyaluronic Acid and Spot Cream Containing Triethyl Citrate, Ethyl Linoleate, GT Peptide-10, Honokiol
Phase 3
Dr.dr.Irma Bernadette, SpKK (K)·Not yet recruiting·Primary completion 1 May 2025·NCT06775314
1 site
PS
A Study to Assess Efficacy and Safety of N-Acetyl-GED-0507-34-LEVO Gel 5% in Patients With Acne Vulgaris (GEDACNE 2)
Phase 3
PPM Services S.A.·Active, not recruiting·Primary completion 1 Mar 2026·NCT07384208
31 sites
PS
A Study to Assess Efficacy and Safety of N-Acetyl-GED-0507-34-LEVO Gel 5%, in Patients With Acne Vulgaris (GEDACNE-1)
Phase 3
PPM Services S.A.·Active, not recruiting·Primary completion 1 Mar 2026·NCT07384195
29 sites
PS
A Long-term Safety and Efficacy Study of N-Acetyl-GED-0507-34-LEVO Gel 5%, in Subjects With Acne Vulgaris (GEDACNE-LT)
Phase 3
PPM Services S.A.·Active, not recruiting·Primary completion 1 Apr 2026·NCT07389109
59 sites
UB
A Study to Test the Long-term Treatment of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa
Phase 3
UCB Biopharma SRL·Active, not recruiting·Primary completion 28 July 2026·NCT04901195
145 sites
658 enrolled·PI: UCB Cares
CH
Clinical Trial to Compare Oral Isotretinoin to Standard of Care in Moderate Acne Skin of Color Patients
Phase 3
Centre Hospitalier Universitaire de Nice·Recruiting·Primary completion 1 Sept 2026·NCT06447480
19 sites
PIs: Thierry Passeron, Marie Beylot-Barry, Marie Lemoigne, Ph, +16
ZS
Efficacy and Safety of Clascoterone Cream 1% in Facial Acne Vulgaris
Phase 3
Zhejiang Sunshine Mandi Pharmaceutical Co.,Ltd.·Recruiting·Primary completion 1 Oct 2026·NCT06403501
1 site
IC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa
Phase 3
Incyte Corporation·Active, not recruiting·Primary completion 26 Dec 2026·NCT06212999
165 sites
617 enrolled
GR
A Study to Compare the Efficacy, Safety and Pharmacokinetics of Trifarotene 50 mcg/g Cream in Chinese Subjects With Acne Vulgaris
Phase 3
Galderma R&D·Recruiting·Primary completion 31 Dec 2026·NCT07186413
1 site
PI: Leihong Xiang
EL
Study of New Antiandrogenic Progestogen + Low-dose Estrogen for Moderate Acne Vulgaris
Phase 3
Eurofarma Laboratorios S.A.·Not yet recruiting·Primary completion 1 Feb 2027·NCT06905210
1 site
N
A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa (RECHARGE 1)
Phase 3
Novartis Pharmaceuticals·Active, not recruiting·Primary completion 17 May 2027·NCT06799000
138 sites
588 enrolled
N
A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa
Phase 3
Novartis Pharmaceuticals·Active, not recruiting·Primary completion 3 June 2027·NCT06840392
131 sites·1 top centre: Northwestern
565 enrolled
ZS
1% Clascoterone Cream for the Treatment Acne Vulgaris
Phase 3
Zhejiang Sunshine Mandi Pharmaceutical Co.,Ltd.·Not yet recruiting·Primary completion 7 Aug 2028·NCT07457294
0 sites
EU
A Full Face Study to Evaluate the Efficacy of Dermapen 4™ Microneedling Device in Addition with MG-CLR Serum for Acne Treatment Over 12 Weeks.
PHASE2/PHASE3
Equipmed USA LLC·Not yet recruiting·Primary completion 1 Mar 2025·NCT06602284
1 site
HU
Effectiveness and Safety of Zingiber Officinale Transdermal Patch for Acne Vulgaris; Study of Interleukin 1 and Skin Microbiome
PHASE2/PHASE3
Hasanuddin University·Active, not recruiting·Primary completion 25 Aug 2025·NCT06787222
1 site
BB
A Study Evaluating BFB759 in Moderate to Severe Hidradenitis Suppurativa
PHASE2/PHASE3
Bluefin Biomedicine, Inc.·Recruiting·Primary completion 1 Aug 2027·NCT07287644
58 sites
N
Study of Efficacy and Safety of Investigational Treatments in Patients With Moderate to Severe Hidradenitis Suppurativa
Phase 2
Novartis Pharmaceuticals·Active, not recruiting·Primary completion 4 Dec 2024·NCT03827798
36 sites
248 enrolledstalled · 187d
BI
Study to Evaluate the Safety and Efficacy of BF-200 ALA (Ameluz®) and BF-RhodoLED® in the Treatment of Moderate to Severe Acne Vulgaris With Photodynamic Therapy in Adults
Phase 2
Biofrontera Inc.·Active, not recruiting·Primary completion 22 Aug 2025·NCT05080764
9 sites
PI: Mitchel P Goldman
UP
The Relationship Between Microbioma Balance and Acne Vulgaris as a New Acne Treatment
Phase 2
Universitas Padjadjaran·Not yet recruiting·Primary completion 31 Dec 2025·NCT06925386
1 site
UO
Anifrolumab for Hidradenitis Suppurativa
Phase 2
University of North Carolina, Chapel Hill·Active, not recruiting·Primary completion 22 Jan 2026·NCT06374212
1 site
PI: Christopher Sayed
A,
A Study to Evaluate the Efficacy and Safety of AVTX-009 in Patients With Moderate to Severe Hidradenitis Suppurativa
Phase 2
Avalo Therapeutics, Inc.·Active, not recruiting·Primary completion 23 Feb 2026·NCT06603077
89 sites
253 enrolled
SP
Topical Application of Engineered Lactobacillus Reuteri With a Zinc Sulfate-Tannic Acid MPN Coating for Acne
Phase 2
Shenzhen People's Hospital·Recruiting·Primary completion 30 Mar 2026·NCT07366229
1 site
XH
Study to Evaluate the Efficacy, Safety and Tolerability of Photodynamic Therapy(PDT) With Chlorin-e6 in Treating Moderate to Severe Acne
Phase 2
Xiyuan Hospital of China Academy of Chinese Medical Sciences·Recruiting·Primary completion 30 Sept 2026·NCT06311890
1 site
PI: Huiyan Chi, doctor
AU
Topical 5% Spironolactone Gel Versus 0.1% Adapalene Gel for Acne Vulgaris: A Randomized Split-Face Study
Phase 2
Assiut University·Not yet recruiting·Primary completion 1 Oct 2026·NCT07473895
1 site
JK
Safety, Efficacy and Pharmacokinetic Characteristics of KR230109 Cream in Facial Acne Vulgaris
Phase 2
Jiangxi Kvvit Pharmaceutical Co., Ltd.·Not yet recruiting·Primary completion 30 Oct 2026·NCT07345390
0 sites
ZB
Tibulizumab Skin Healing and Inflammation Evaluation for Lasting Defense
Phase 2
Zura Bio Inc·Recruiting·Primary completion 1 Nov 2026·NCT06993610
56 sites
IC
Pharmacokinetics, Safety, and Efficacy of Povorcitinib in Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa
Phase 2
Incyte Corporation·Recruiting·Primary completion 25 Mar 2028·NCT07213973
29 sites·1 top centre: Johns Hopkins
SU
Clascoterone for Steroid-related Acne Vulgaris in Transgender Male Patients Receiving Masculinizing Hormone Therapy
PHASE1/PHASE2
Stanford University·Recruiting·Primary completion 1 Dec 2025·NCT05891795
SH
A Study to Evaluate Efficacy and Safety of HB0043 in Aadult Patients With Moderate to Severe Acne Vulgaris.
PHASE1/PHASE2
Shanghai Huaota Biopharmaceutical Co., Ltd.·Not yet recruiting·Primary completion 27 Oct 2026·NCT07449156
UO
Lipidome and Microbiome Profile of Acne
PHASE1/PHASE2
University of California, Davis·Active, not recruiting·Primary completion 1 Jan 2027·NCT02713607
YF
Comparative Effectiveness of Clindamycin-Retinoid, Clindamycin-Retinoid-Dexamethasone, and 10% SM-hUCMSC Secretome Gel in the Improvement of Mild-to-Moderate Acne Vulgaris
PHASE1/PHASE2
Yohanes Firmansyah, dr, MH, MM·Not yet recruiting·Primary completion 18 Mar 2027·NCT07504822
SP
Study to Evaluate Safety, Efficacy and Immunogenicity of Acne mRNA Vaccine in Adults With Moderate to Severe Acne
PHASE1/PHASE2
Sanofi Pasteur, a Sanofi Company·Recruiting·Primary completion 31 Aug 2028·NCT06316297
SP
Study to Evaluate Safety, Efficacy and Immunogenicity of Acne mRNA Vaccine in Participants With Mild Acne
PHASE1/PHASE2
Sanofi Pasteur, a Sanofi Company·Recruiting·Primary completion 19 June 2029·NCT07013747